Georgia's Online Cancer Information Center


back

Find A Treatment Site

Northwest Georgia Oncology Centers (NGOC) - Cobb Hospital (Marietta)

Online Referral Form: https://ngoc.com/onlinereferral/

Treatment Sites in Georgia

Primary Location

340 Kennestone Hospital Blvd.
Suite 100
Marietta, GA 30060
770-281-5101 (p)


driving directions

Clinical Trials in Georgia

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Cancer Type: Breast Cancer, Unknown Primary
Study Coordinator: Kristine Parker - 770-281-5101

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Cancer Type: Lung Cancer
Study Coordinator: Kristine Parker - 770-281-5101

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Cancer Type: Leukemia
Study Coordinator: Kristine Parker - 770-281-5101

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Cancer Type: Breast Cancer, Unknown Primary
Study Coordinator: Kristine Parker - 770-281-5101

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Cancer Type: Esophogeal Cancer, Stomach/ Gastric Cancer, Unknown Primary

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Cancer Type: Lung Cancer, Unknown Primary
Study Coordinator: Kristine Parker - 770-281-5101

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Cancer Type: Breast Cancer
Study Coordinator: Kristine Parker - 770-281-5101
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Find Cancer Care

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

Georgia CORE

 

Georgia CORE bridges the gap between groundbreaking research, educational outreach, and effective advocacy to transform the landscape of cancer care for all Georgians.